Impact of Obesity on the Expression Profile of Natriuretic Peptide System in a Rat Experimental Model

PLoS ONE

Volumn 8, Issue 8, 2013, Pages

  Cabiati, Manuela ^a   Raucci, Serena ^a   Liistro, Tiziana ^b   Belcastro, Eugenia ^a   Prescimone, Tommaso ^a   Caselli, Chiara ^a   Matteucci, Marco ^b   Iozzo, Patricia ^a   Mattii, Letizia ^c   Giannessi, Daniela ^a   Del Ry, Silvial ^a  

^a INSTITUTE OF CLINICAL PHYSIOLOGY   (Italy)

^b SCUOLA SUPERIORE SANT ANNA   (Italy)

^c UNIVERSITY OF PISA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ATRIAL NATRIURETIC FACTOR; BRAIN NATRIURETIC PEPTIDE; INTERLEUKIN 6; MESSENGER RNA; NATRIURETIC FACTOR; NATRIURETIC PEPTIDE RECEPTOR A; NATRIURETIC PEPTIDE RECEPTOR B; NATRIURETIC PEPTIDE RECEPTOR C; NATRIURETIC PEPTIDE TYPE C; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANP GENE; ARTICLE; BNP GENE; CNP GENE; CONTROLLED STUDY; GENE EXPRESSION PROFILING; GENETIC ANALYSIS; GENETIC VARIABILITY; HEART MUSCLE; IL 6 GENE; IMMUNOHISTOCHEMISTRY; KIDNEY PARENCHYMA; LUNG PARENCHYMA; MALE; NONHUMAN; NPR A GENE; NPR B GENE; NPR C GENE; NUCLEOTIDE SEQUENCE; OBESITY; PROTEIN EXPRESSION; RAT; REAL TIME POLYMERASE CHAIN REACTION; TNF ALPHA GENE; TRANSCRIPTOMICS;

ANIMALS; CYTOKINES; DISEASE MODELS, ANIMAL; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; INFLAMMATION MEDIATORS; KIDNEY; LUNG; MALE; MYOCARDIUM; NATRIURETIC PEPTIDE, BRAIN; NATRIURETIC PEPTIDES; OBESITY; RATS; RATS, ZUCKER; TRANSCRIPTOME;

EID: 84883255799     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0072959     Document Type: Article

References (63)

1. James PT, (2004) Obesity: the worldwide epidemic. Clin Dermatol 22: 276-280.
2. Eckel RH, Kahn R, Robertson RM, Rizza RA, (2006) Preventing cardiovascular disease and diabetes: a call to action from the American Diabetes Association and the American Heart Association. Diabetes Care 29: 1697-1699.
3. Ogden CL, Carroll MD, Curtin LR, McDowell MA, Tabak CJ, et al. (2006) Prevalence of overweight and obesity in the United States, 1999-2004. JAMA 295: 1549-1555.
4. Kopelman PG, (2000) Obesity as a medical problem. Nature 404: 635-643.
5. Martin LF, Robinson A, Moore BJ, (2000) Socioeconomic issues affecting the treatment of obesity in the new millennium. Pharmacoeconomics 18: 335-353.
6. Antic V, Dulloo A, Montani JP, (2003) Multiple mechanisms involved in obesity-induced hypertension. Heart Lung Circ 12: 84-93.
7. Kuchta KF, (2005) Pathophysiologic changes of obesity. Anesthesiol Clin North America 23: 421-429.
8. Rubenstein AH, (2005) Obesity: a modern epidemic. Trans Am Clin Climatol Assoc 116: 103-111.
9. Poirier P, Giles TD, Bray GA, Hong Y, Stern JS, et al. (2006) Obesity and cardiovascular disease: pathophysiology, evaluation, and effect of weight loss. Arterioscler Thromb Vasc Biol 26: 968-976.
10. Singer G, Granger N, (2007) Inflammatory responses underlying the microvascular dysfunction associated with obesity and insulin resistance. Microcirc 14: 375-387.
11. Frisbee JC, Delp MD, (2006) Vascular function in the metabolic syndrome and the effects on skeletal muscle perfusion: lessons from the obese Zucker rat. Essays Biochem 4: 145-161.
12. Funahashi T, Matsuzawa Y, (2007) Metabolic syndrome: Clinical concept and molecular basis. Annals Med 39: 482-494.
13. Eckel RH, Grundy SM, Zimmet PZ, (2005) The metabolic syndrome. Lancet 365: 1415-1428.
14. Einhorn D, Reaven GM, Cobin RH, Ford E, Ganda OP, et al. (2003) American College of Endocrinology position statement on the insulin resistance syndrome. Endocr Pract 9: 237-252.
15. Dandona P, Ajada A, Chaudhuri A, Mohanty P, Garg R, (2005) Metabolic syndrome: a comprehensive perspective based on interactions between obesity, diabetes and inflammation. Circulation 111: 1448-1454.
16. Rubattu S, Sciarretta S, Valenti V, Stanzione R, Volpe M, (2008) Natriuretic peptides: an update on bioactivity, potential therapeutic use and implication in cardiovascular diseases. Am J Hypertens 21: 733-741.
17. Levin E, Gardner D, Samson W, (1998) Natriuretic peptides. N Engl J Med 339: 321-328.
18. Gardner DG, (2003) Natriuretic peptides: markers or modulators of cardiac hypertrophy? Trends Endocrinol Metab 14: 411-416.
19. Kuhn M, (2003) Structure, regulation, and function of mammalian membrane guanylyl cyclase receptors, with a focus on guanylyl cyclase-A. Circ Res 93: 700-709.
20. Licata G, Volpe M, Scaglione R, Rubattu S, (1994) Salt-regulating hormones in young normotensive obese subjects. Effects of saline load. Hypertension 23: I20-4.
21. Horwich TB, Hamilton MA, Fonarow GC, (2006) B-type natriuretic peptide levels in obese patients with advanced heart failure. JACC47: 85-90.
22. Bayes-Genis A, DeFilippi C, Jannuzzi JL, (2008) Understanding amino-terminal pro-B-type natriuretic peptide in obesity. Am J Cardiol 101: 89-94.
23. Maisel A, Mueller C, (2008) North America B-type natriuretic peptide (BNP) consensus working group. Congest Heart Fail 14: 4.
24. Ahn SM, Yoo BS, (2010) Two problems with analyzing natriuretic peptide levels: obesity and acute myocardial infarction. Korean Circ J 40: 550-551.
25. Sengenes C, Berlan M, De Ghsezinski I, Lafontan M, Gahtzky J, (2000) Natriuretic peptides: a new lipolytic pathway in human adipocytes. FASEB J 14: 1345-1351.
26. Kalra PR, Tigas S, (2002) Regulation of lipolysis, natriuretic peptides and the development of cachexia. Int J Cardiol 85: 125-132.
27. Dessì-Fulgheri P, Sarzani R, Rappelli A, (2003) Role of the natriuretic peptide system in lipogenesis/lipolysis. Nutr Metab Cardiovasc Dis 13: 244-249.
28. Katafuchi T, Garbers DL, Albanese JP, (2010) CNP/GC-B system: a new regulator of adipogenesis. Peptides 31: 1906-1911.
29. Kershaw EE, Flier JS, (2004) Adipose tissue as an endocrine organ. J Clin Endocrinol Metab 89: 2548-56.
30. Maccio A, Madeddu C, Mantovani G, (2009) Adipose tissue as target organ in the treatment of hormone-dependent breast cancer: new therapeutic perspectives. Obesity Rev 10: 660-670.
31. Cozzi J, Anegon I, Braun V, Gross AC, Merrouche C, et al. (2009) Pronuclear DNA injection for the production of transgenic rats. Methods Mol Biol 561: 73-88.
32. Geurts AM, Cost GJ, Freyvert Y, Zeitler B, Miller JC, et al. (2009) Knockout rats via embryo microinjection of zinc-finger nucleases. Science 325: 433.
33. Bray GA, (1977) The Zucker fatty rat: a review. Fed Proc 36: 148-153.
34. Frisbee JC, (2005) Hypertension-indipendent microvascular rarefaction in the obese Zucker rat model of metabolic syndrome. Microcirc 12: 383-392.
35. Vaziri ND, Xu ZG, Shahkarami A, Huang KT, Rodriguez-Iturbe B, et al. (2005) Role of AT-1 receptor in regulation of vascular MCP-1, IL-6, PAI-1 MAP kinase, and matrix expressions in obesity. Kidney Int 68: 2787-2793.
36. Johnson FK, Johnson RA, Durante W, Jackson KE, Stevenson BK, et al. (2006) Metabolic syndrome increases endogenous carbon monoxide production to promote hypertension and endothelial dysfunction in obese Zucker rat. Am J Physiol Regul Integr Comp Physiol 290: R601-608.
37. Guiducci L, Liistro T, Burchielli S, Panetta D, Bonora D, et al. (2011) Contribution of organ blood flow, intrinsic tissue clearance and glycemia to the regulation of glucose use in obese and type 2 diabetic rats: a PET study. Nutr Metab Cardiovasc Dis 21: 726-732.
38. Del Ry S, Cabiati M, Lionetti V, Emdin M, Recchia FA, et al. (2008) Expression of C-type natriuretic peptide and of its receptor NPR-B in normal and failing heart. Peptides 29: 2208-2215.
39. Del Ry S, Cabiati M, Lionetti V, Simioniuc A, Caselli C, et al. (2009) Asymmetrical myocardial expression of natriuretic peptides in pacing-induced heart failure. Peptides 30: 1710-1713.
40. Cabiati M, Raucci S, Caselli C, Guzzardi MA, D'Amico A, et al. (2012) Tissue-specific selection of stable reference genes for real-time PCR normalization in an obese rat model. J Molec Endocrinol 48: 251-260.
41. Lowry OH, Rosebrough A, Farr A, Randall RJ, (1951) Protein measurement with the folin phenol reagent. JBiol Chem 193: 265-267.
42. Del Ry S, Cabiati M, Vozzi F, Battolla B, Caselli C, et al. (2011) Expression of C-type natriuretic peptide and its receptor NPR-B in cardiomyocytes. Peptides 32: 1713-1718.
43. Pilo A, Zucchelli GC, Malvano R, Masini S, (1982) Main features of computer algorithms for RIA data reduction. Comparison of same different approaches for the interpolation of dose-response curve. J Nucl Med All Sci 26: 235-248.
44. Miyashita K, Itoh H, Tsujimoto H, Tamura N, Fukunaga Y, et al. (2009) Natriuretic peptides/cGMP/cGMP-dependent protein kinase cascades promote muscle mitochondrial biogenesis and prevent obesity. Diabetes 58: 2880-2892.
45. Clerico A, Giannoni A, Vittorini S, Emdin M, (2012) The paradox of low BNP levels in obesity. Heart Fail Rev 17: 81-96.
46. Abassi Z, Karram T, Ellaham S, Winaver J, Hoffman A, (2004) Implications of the natriuretic peptide system in the pathogenesis of heart failure: diagnostic and therapeutic importance. Pharm Ther. 102: 223-41.
47. Barr CS, Rhodes P, Struthers AD, (1996) C-type natriuretic peptide. Peptides. 17: 1243-51.
48. Scotland RS, Ahluwalia A, Hobbs AJ, (2005) C-type natriuretic peptide in vascular physiology and disease. Pharm Ther. 105: 85-93.
49. Moro C, Smith SR, (2009) Natriuretic peptides: new players in energy homeostasis. Diabetes 58: 2726-2728.
50. Savoia C, Volpe M, Alonzo A, Rossi C, Rubattu S, (2010) Natriuretic peptides and cardiovascular damage in the metabolic syndrome: molecular mechanisms and clinical implications. Clin Sci 118: 231-240.
51. Yasunari K, Kohno M, Hanehira T, Minami M, Ikeda M, et al. (1995) Elevated glucose concentration and natriuretic peptides receptor response on vascular smooth muscle of spontaneously hypertensive rats. Clin Exp Pharmacol Physiol 22: S180-182.
52. Yoshimoto T, Naruse M, Naruse K, Arai K, Imaki T, et al. (1996) Vascular action of circulating and local natriuretic peptide system is potentiated in obese/hyperglicemic and hypertensive rats. Endocrinology 137: 5552-5557.
53. Nunes S, Soares E, Fernandes J, Viana S, Carvalho E, et al. (2013) Early cardiac changes in a rat model of prediabetes: brain natriuretic peptide overexpression seems to be the best marker. Cardiovasc Diabetol 12: 44.
54. Mifune H, Suzuki S, Honda J, Kobayashi Y, Noda Y, et al. (1992) Atrial natriuretic peptide (ANP): a study of ANP and its mRNA in cardiocytes, and of plasma ANP levels in non-obese diabetic mice. Cell Tissue Res 267: 267-272.
55. Horwich TB, Hamilton MA, Fonarow GC, (2006) B-type natriuretic peptide levels in obese patients with advanced heart failure. J Am Coll Cardiol 47: 85-90.
56. Strohacker K, McFarlin BK, (2010) Influence of obesity, physical inactivity, and weight cycling on chronic inflammation. Front Biosci E2: 98-104.
57. Wang Z, Nakayama T, (2012) Inflammation, a Link between Obesity and Cardiovascular Disease. Mediators Inflam 2010: ID535918.
58. Vykoukal D, Davies MG, (2011) Vascular biology of metabolic syndrome. J Vasc Surg 54: 819-831.
59. Mohamed-Ali V, Pinkney JH, Coppack SW, (1998) Adipose tissue as an endocrine and paracrine organ. Int J Obes 22: 1145-1158.
60. Bastard JP, Jardel C, Bruckert E, Blondy P, Capeau J, et al. (2000) Elevated levels of interleukin 6 are reduced in serum and subcutaneous adipose tissue of obese women after weight loss. J Clin Endocrinol Metab 85(9): 3338-42.
61. Caro JF, Sinha MK, Kolaczybski JW, Zhang PL, Considine RV, (1996) Leptin: the tale of an obesity gene. Diabetes 45: 1455-1462.
62. Hotamisligil GS, Shargill NS, Spiegelman BM, (1993) Adipose expression of tumor necrosis factor-a: direct role in obesity-linked insulin resistance. Science 259: 87-91.
63. Mohamed-Ali V, Goodrick S, Rawesh A, Katz DR, Miles JM, et al. (1997) Subcutaneous adipose tissue releases interleukin-6, but not tumor necrosis factor-a, in vivo. J Clin Endocrinol Metab 82: 4196-4200.